EDAP TMS S.A. ADR (FOCL)
NASDAQ: FOCLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FOCL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $123.25M
- EPS (TTM)
- -$1.35
- Dividend yield
- None
- 52-week range
- 2.11 – 6.40
- Day range
- 2.55 – 3.10
- Volume / Avg
- 143.15K / 137.30K
- Beta
- —
- Shares outstanding
- 47.22M
52-week range
FOCL stock today
Shares of EDAP TMS S.A. (FOCL) finished lower on Nov 20 at $2.61, a drop of 7.45% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, FOCL sits near the bottom of its 52-week range of $2.11 to $6.40: 59.2% below the high, set on Aug 4, 2026 and 23.7% above the low. FOCL is down 20.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 13.5%.
EDAP TMS S.A. has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About EDAP TMS S.A.
Company profileEDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Ryan Rhodes
- Headquarters
- Vaulx-En-Velin
- Employees
- 289
- Website
- investor.focalone.com
Financial highlights
Full financialsIn fiscal 2025, EDAP TMS S.A. generated $70.5 million in revenue, up 1.6% from fiscal 2024. EDAP TMS S.A. reported a net loss of $29.2 million, compared with a loss of $20.6 million a year earlier. Gross margin was 42.5% (up from 41.4%) and operating margin -35.0%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $70.53M | $69.39M |
| Growth | +1.63% | — |
| Net income | $-29.25M | $-20.58M |
| EPS (diluted) | $-0.78 | $-0.55 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$8.30+218.01%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.10 vs $-0.18
- Surprise
- +44.44%
FOCL news
All FOCL newsEDAP TMS S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VANIVivani Medical Inc. | 1.14 | +4.59% | $102.83M | vs FOCL |
| STXSStereotaxis Inc. | 0.9422 | -6.71% | $95.03M | vs FOCL |
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs FOCL |
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs FOCL |
| ELMDElectromed Inc. | 22.98 | -1.20% | $187.84M | vs FOCL |
| HYPRHyperfine Inc. Class A | 0.5465 | +4.27% | $57.96M | vs FOCL |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs FOCL |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs FOCL |
Indexes, lists and sector
EDAP TMS S.A. stock FAQ
What is EDAP TMS S.A.'s stock price today?
FOCL last traded at $2.61 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.
Who is EDAP TMS S.A.'s CEO?
Mr. Ryan Rhodes is the chief executive officer of EDAP TMS S.A. ADR, which has about 289 employees.
What is the FOCL 52-week high?
The 52-week high for FOCL is $6.40 and the 52-week low is $2.11. The stock is currently 59.2% below its high.